Soligenix Submits Type A Meeting Request to U.S. FDA for HyBryte™ New Drug Application in the Treatment of Cutaneous T-Cell LymphomaPRNewsWire • 03/09/23
Soligenix Receives Refusal to File Letter from U.S. FDA for HyBryte™ New Drug Application in the Treatment of Cutaneous T-Cell LymphomaPRNewsWire • 02/14/23
Soligenix Announces Distribution of Series D Preferred Stock to Holders of its Common StockPRNewsWire • 12/23/22
Soligenix Announces Publication Demonstrating Positive Correlates of Protection with RiVax® in Non-Human Primate Survival after Ricin ChallengePRNewsWire • 12/20/22
Soligenix Initiates Phase 2 Clinical Trial of SGX302 (synthetic hypericin) for the Treatment of Mild-to-Moderate PsoriasisPRNewsWire • 12/19/22
Soligenix Announces Submission of New Drug Application to the FDA for HyBryte™ in the Treatment of Cutaneous T-cell LymphomaPRNewsWire • 12/15/22
Soligenix to Receive $1.2 M in Non-Dilutive Funding Through New Jersey Technology Business Tax Certificate Transfer ProgramPRNewsWire • 11/15/22
Soligenix Announces Recent Accomplishments And Third Quarter 2022 Financial ResultsPRNewsWire • 11/10/22
Soligenix Invited to Submit BARDA Contract Proposal for Development of Thermostabilized Subunit Vaccines for Sudan Ebola and Marburg VirusesPRNewsWire • 10/27/22
Soligenix Announces Adjournment of Annual Meeting and Information for Reconvened MeetingPRNewsWire • 10/20/22
Soligenix: A Biotech Bargain Ready To File For Approval In Cutaneous T-Cell LymphomaSeeking Alpha • 10/05/22
Soligenix Announces Partial Adjournment of Annual Meeting and Information for Reconvened Annual MeetingPRNewsWire • 09/23/22
FDA Awards $2.6 Million Grant for Expanded Study of Soligenix's Hybryte(TM) for CTCLNewsfile Corp • 09/12/22
Soligenix to Present at the H.C. Wainwright 24th Annual Global Investment ConferencePRNewsWire • 09/08/22
U.S. Food and Drug Administration Awards $2.6 Million Orphan Products Development Grant for Expanded Study of HyBryte™ in the Treatment of Cutaneous T-Cell LymphomaPRNewsWire • 09/06/22
Soligenix Announces Recent Accomplishments And Second Quarter 2022 Financial ResultsPRNewsWire • 08/12/22
Soligenix Receives Agreement from FDA on Initial Pediatric Study Plan for HyBryte™ for the Treatment of Cutaneous T-Cell LymphomaPRNewsWire • 07/27/22